Literature DB >> 23085458

Preoperative biopsy and intraoperative tumor diameter predict lymph node dissemination in endometrial cancer.

Mariam M AlHilli1, Karl C Podratz, Sean C Dowdy, Jamie N Bakkum-Gamez, Amy L Weaver, Michaela E McGree, Sanjeev Kumar, Gary L Keeney, William A Cliby, Andrea Mariani.   

Abstract

OBJECTIVE: To determine whether preoperative biopsy (grade and histology) and intraoperative tumor diameter (TD) predict lymph node dissemination (LN+) and lymph node recurrence (LNRec) in endometrial cancer (EC).
METHODS: Patients who underwent EC surgery from 2004 to 2008 were stratified into risk categories. Cases with preoperative grade 3 or non-endometrioid histology were classified as high risk (HR). Patients with preoperative FIGO grade 1 or 2, endometrioid histology or complex and/or atypical hyperplasia were classified based on intraoperative findings: (a) intraoperative macroscopic extrauterine disease classified as HR; (b) largest TD>2 cm classified as intermediate risk (IR) and (c) TD ≤ 2 cm classified as low risk (LR). LN+ and LNRec rates were determined.
RESULTS: Of 704 patients evaluated, 188 were HR (27%), 350 IR (50%), and 166 LR (23%). P/PA lymphadenectomy was performed in 87% HR, 83% IR and 16% LR patients. LN+ and/or LNRec occurred in 51 HR patients (27%) and 39 IR patients (11%). Only 1 LR patient (0.6%) had LN+ and none had LNRec. Four LR patients (2%) required adjuvant therapy according to permanent section pathology.
CONCLUSIONS: Preoperative biopsy and intraoperative TD can be used to effectively stratify patients into LR, IR or HR subgroups to tailor surgery. LR patients have a low probability (<1%) of LN+ and/or LNRec and lymphadenectomy can be omitted in this group. HR and IR patients combined (3/4 of population) have a substantial risk of LN+ or LNRec (17%). Lymphadenectomy is proposed to be advantageous in HR and IR patients if accurate frozen section is lacking. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2012        PMID: 23085458     DOI: 10.1016/j.ygyno.2012.10.009

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  24 in total

1.  Does Obesity Affect Pathologic Agreement of Initial and Final Tumor Grade of Disease in Endometrial Cancer Patients?

Authors:  Laura R Daily; Jonathan D Boone; Hannah C Machemehl; Eric D Thomas; Gerald McGwin; J Michael Straughn; Charles A Leath
Journal:  Int J Gynecol Cancer       Date:  2017-05       Impact factor: 3.437

Review 2.  The role of para-aortic lymphadenectomy in endometrial cancer.

Authors:  Mariam M AlHilli; Andrea Mariani
Journal:  Int J Clin Oncol       Date:  2013-02-15       Impact factor: 3.402

3.  Association of Tumor Size With Myometrial Invasion, Lymphovascular Space Invasion, Lymph Node Metastasis, and Recurrence in Endometrial Cancer: A Meta-Analysis of 40 Studies With 53,276 Patients.

Authors:  Xiaoying Jin; Chunjuan Shen; Xiaodi Yang; Yayuan Yu; Jianzhang Wang; Xuan Che
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

4.  Association of Tumor Size With Prognosis in Patients With Resectable Endometrial Cancer: A SEER Database Analysis.

Authors:  Xuefei Hou; Suru Yue; Jie Liu; Zhiqing Qiu; Liming Xie; Xueying Huang; Shasha Li; Liren Hu; Jiayuan Wu
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

5.  Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion.

Authors:  Ane Gerda Zahl Eriksson; Jen Ducie; Narisha Ali; Michaela E McGree; Amy L Weaver; Giorgio Bogani; William A Cliby; Sean C Dowdy; Jamie N Bakkum-Gamez; Nadeem R Abu-Rustum; Andrea Mariani; Mario M Leitao
Journal:  Gynecol Oncol       Date:  2015-12-31       Impact factor: 5.482

Review 6.  Role of pelvic and para-aortic lymphadenectomy in endometrial cancer: current evidence.

Authors:  Giorgio Bogani; Sean C Dowdy; William A Cliby; Fabio Ghezzi; Diego Rossetti; Andrea Mariani
Journal:  J Obstet Gynaecol Res       Date:  2014-02       Impact factor: 1.730

7.  Contemporary Incidence of Medical Inoperability in Clinical Stage I Endometrial Cancer.

Authors:  Michelle Ertel; S Allison Staley; Tam Nguyen; Austin Johnson; Austin Hopkins; Nerlyne Desravines; Johnathon Recknagel; Xinyi Zhang; Xianming Tan; Leslie H Clark
Journal:  Ann Surg Oncol       Date:  2021-06-18       Impact factor: 5.344

8.  Small endometrial carcinoma 10 mm or less in diameter: clinicopathologic and histogenetic study of 131 cases for early detection and treatment.

Authors:  Katsuhiko Hasumi; Yuko Sugiyama; Kimihiko Sakamoto; Futoshi Akiyama
Journal:  Cancer Med       Date:  2013-09-30       Impact factor: 4.452

9.  Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer.

Authors:  L Helpman; R Kupets; A Covens; R S Saad; M A Khalifa; N Ismiil; Z Ghorab; V Dubé; S Nofech-Mozes
Journal:  Br J Cancer       Date:  2013-12-24       Impact factor: 7.640

Review 10.  Lymph node assessment in endometrial cancer: towards personalized medicine.

Authors:  Fabien Vidal; Arash Rafii
Journal:  Obstet Gynecol Int       Date:  2013-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.